Analyses of peripheral blood samples from patients with advanced non-small cell lung cancer (NSCLC) showed that paclitaxel treatment increases the percentage of Teff cells, and decreases Treg cells levels, but did not affect the number of CD8+ T cells and CD19+ B cells [76]. This evidence concerns the gene CD19 and non-small cell lung carcinoma.